CO2 Solution Announces CDN$2 Million Equity Investment by Codexis and Collaboration in Carbon Capture
Joint Development Agreement to combine Codexis' industrially robust enzymes with CO2 Solution's carbon capture technology
TSX-V: CST Outstanding shares: 60,261,136
Under the collaboration, CO2 Solution's proprietary enzymatic method for the efficient capture of carbon dioxide from coal-fired power plants and other large sources of emissions will be combined with Codexis' directed enzyme evolution technology. Coal-fired power plants are major emitters of carbon dioxide, a significant greenhouse gas (GHG) believed to contribute to global warming. CO2 Solution's technology uses the natural enzyme carbonic anhydrase to enhance CO2 absorption efficiency from power plant emissions, at lower cost than conventional technology. Codexis' technology will be used to improve this enzyme's ability to function in harsh industrial conditions. Carbonic anhydrase is found in humans and other mammals and is critical in the efficient management of CO2 during respiration.
Highlights of the Joint Development Agreement also include the following:
- The initial term of the JDA is until January 31, 2011 and may be extended or replaced by another form of association upon mutual agreement. - CO2 Solution and Codexis will work exclusively with each other in the field of carbon capture for the term of the agreement. - The agreement encompasses the economic validation of the enzymatic carbon capture technology with CO2 Solution responsible for processes, testing and enzyme delivery systems, and Codexis responsible for enzyme development and manufacturing. - CO2 Solution and Codexis will cooperate on Canadian and U.S. government funding opportunities for the technology as well as customer and adopter opportunities. - Codexis will pay an immediate Commitment Fee to CO2 Solution in the amount of $475,000 that is refundable under certain events.
Under a subscription agreement entered into between Codexis and CO2 Solution, Codexis acquired 10,000,000 common shares of CO2 Solution by way of private placement at a price of
"Coal-fired power plants will be a major source of energy for many years to come, yet high cost is a significant current barrier to adoption of carbon dioxide capture technology at these plants. Cost-effective carbon capture at these and other large emissions sources is an important step toward managing carbon dioxide emissions," said
Commenting on the agreements,
Codexis, Inc. is a clean technology company headquartered in
About CO2 Solution
Based in Quebec City, CO2 Solution Inc. has developed a proprietary bio-technological platform for the efficient capture of carbon dioxide (CO2), the most important greenhouse gas (GHG), from power plants and other large stationary sources of emissions. The Company's technology platform exploits the natural power of a bio-catalyst (enzyme), carbonic anhydrase, which functions within humans and other mammals to manage CO2 during respiration. CO2 Solution has successfully adapted the enzyme to function within an industrial environment, and thus has taken advantage of a biomimetic approach to CO2 capture based on millions of years of evolution. The Company is commercializing its technology for coal fired power generation, the oil sands and other CO2-intensive industries where a low-cost capture solution is key to meeting climate change legislation in a cost effective manner.
CO2 Solution's technology platform is protected by several North American and European patents, including the use of carbonic anhydrase for CO2 capture and release in a packed column system. News releases and additional information can be found at www.co2solution.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE CO2 SOLUTION INC.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.